Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.99%
1,093.81
+10.77
+0.99%
—1,083.041,082.631,099.011,080.59——
SIXC
Communications
SIXC
Communications
SIXC
+1.06%
608.77
+6.39
+1.06%
—602.38602.38609.75599.75——
SIXE
Energy
SIXE
Energy
SIXE
+0.96%
1,254.81
+11.98
+0.96%
—1,242.831,229.311,258.881,220.51——
SIXI
Industrials
SIXI
Industrials
SIXI
+2.76%
1,761.11
+47.29
+2.76%
—1,713.821,715.471,763.111,715.47——
SIXM
Financials
SIXM
Financials
SIXM
+0.40%
642.58
+2.59
+0.40%
—639.99636.98644.04631.81——
SIXR
Staples
SIXR
Staples
SIXR
+1.63%
851.13
+13.67
+1.63%
—837.46840.30852.55840.30——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.76%
217.98
+3.76
+1.76%
—214.22214.22218.25214.05——
SIXT
Technology
SIXT
Technology
SIXT
+0.23%
3,211.83
+7.45
+0.23%
—3,204.383,215.043,217.443,159.90——
SIXU
Utilities
SIXU
Utilities
SIXU
+2.55%
948.98
+23.60
+2.55%
—925.38927.91949.76927.91——
SIXV
Health care
SIXV
Health care
SIXV
+2.20%
1,474.52
+31.81
+2.20%
—1,442.711,443.011,477.901,443.01——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+1.30%
2,392.12
+30.78
+1.30%
—2,361.342,391.002,399.182,354.52——
Q1 2026 earnings • released • EPS beat +1.43% • Revenue beat +2.48%
See results
A1ZN34:BVMF
Astrazeneca Plc Bdr
R$154.70
0.00%
(0.00) 1D
Apr 30, 5:05:00 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for A1ZN34...
Open
R$155.72
High
R$156.45
Low
R$154.70
Mkt. cap
211.83B
Avg. vol.
375.00
Volume
458.00
52-wk high
R$190.40
52-wk low
R$123.80
Shares outstanding
1.55B
No. of employees
96K
News stories
From sources across the web
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, UK; Gothenburg, Sweden; and Gaithersburg, Maryland, US. AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About Astrazeneca Plc Bdr
CEOPascal Soriot
Employees96.1K
FoundedApr 6, 1999
HeadquartersCambridge, Cambridgeshire, United Kingdom
SectorPharmaceutical industry
Websiteastrazeneca.com
Last report
Apr 29, 2026
Fiscal Period
Q1 2026
Normalized EPS / Estimate
1.29/ (1.27 est.)USD
+1.43%beat
Revenue / Estimate
15.29B/ (14.92B est.)USD
+2.48%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
14.46B
15.19B
15.50B
15.29B
Cost of goods sold
2.55B
2.79B
3.17B
-
Cost of revenue
2.55B
2.79B
3.17B
-
Research and development expenses
3.51B
3.63B
3.62B
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.98B
5.20B
5.32B
-
Operating expense
8.42B
8.74B
8.99B
-
Total operating expenses
10.97B
11.53B
12.16B
-
Operating income
3.49B
3.66B
3.35B
-
Other non operating income
-
-
-247.00M
-
EBT including unusual items
3.13B
3.24B
2.63B
-
EBT excluding unusual items
3.11B
3.32B
3.05B
-
Income tax expense
679.00M
709.00M
300.00M
-
Effective tax rate
21.71%
21.86%
11.41%
-
Other operating expenses
-72.00M
-89.00M
53.00M
-
Net income
2.45B
2.53B
2.33B
-
Net profit margin
16.95%
16.67%
15.00%
20.15%
Earnings per share
2.17
2.38
2.12
1.29
Interest and investment income
65.00M
85.00M
135.00M
-
Interest expense
-436.00M
-434.00M
-155.00M
-
Net interest expenses
-371.00M
-349.00M
-20.00M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
4.88B
5.21B
4.11B
-
Gain or loss from assets sale
-21.00M
-31.00M
-37.00M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer